The TigerMed-backed clinical research provider reportedly secured near to $100m in a round co-led by Sequoia Capital China and GL Ventures.

PharmaLegacy, a China-based clinical research provider backed by clinical research services provider Tigermed, has raised almost $100m in new funding, DealStreetAsia has reported.

Venture capital firm Sequoia Capital China co-led the round with hedge fund manager Hillhouse Capital’s GL Ventures unit.

The round also featured Prosperico Ventures, Med-Fine Capital, GT Capital, Development Venture Capital Holding, Elikon Venture and Yinglian Healthcare Fund.

Founded in 2008, PharmaLegacy carries out clinical research for pharmaceutical companies in areas such as oncology, respiratory and autoimmune…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn